Literature DB >> 23447881

Equine colostral carbohydrates reduce lipopolysaccharide-induced inflammatory responses in equine peripheral blood mononuclear cells.

J C Vendrig1, L E Coffeng, J Fink-Gremmels.   

Abstract

REASONS FOR PERFORMING STUDY: Increasing evidence suggests that reactions to lipopolysaccharide (LPS), particularly in the gut, can be partly or completely mitigated by colostrum- and milk-derived oligosaccharides. Confirmation of this hypothesis could lead to the development of new therapeutic concepts.
OBJECTIVES: To demonstrate the influence of equine colostral carbohydrates on the inflammatory response in an in vitro model with equine peripheral blood mononuclear cells (PBMCs).
METHODS: Carbohydrates were extracted from mare colostrum, and then evaluated for their influence on LPS-induced inflammatory responses in PBMCs isolated from the same mares, mRNA expression of tumour necrosis factor-alpha, interleukin-6 and interleukin-10 was measured as well as the protein levels of tumour necrosis factor-alpha (TNF-alpha) and interleukin-10 (IL-10).
RESULTS: Equine colostral carbohydrates significantly reduced LPS-induced TNF-alpha protein at both times measured and significantly reduced LPS-induced TNF-alpha, IL-6 and IL-10 mRNA expression by PBMCs. Moreover, cell viability significantly increased in the presence of high concentrations of colostral carbohydrates.
CONCLUSIONS: Carbohydrates derived from equine colostrum reduce LPS-induced inflammatory responses of equine PBMCs. POTENTIAL RELEVANCE: Colostrum and milk-derived carbohydrates are promising candidates for new concepts in preventive and regenerative medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23447881     DOI: 10.1111/j.2042-3306.2012.00680.x

Source DB:  PubMed          Journal:  Equine Vet J Suppl


  1 in total

1.  Effects of orally administered galacto-oligosaccharides on immunological parameters in foals: a pilot study.

Authors:  Johannes Cornelis Vendrig; Luc Edgar Coffeng; Johanna Fink-Gremmels
Journal:  BMC Vet Res       Date:  2014-11-19       Impact factor: 2.741

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.